Nemes Rush Group’s AstraZeneca AZN Stock Holding History

Nemes Rush Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$21.8K	Hold	135	–	–	﹤0.01%	461
2026 Q2	$25.5K	Buy	+135	New	+$25.4K	﹤0.01%	458
2026 Q1	–	Sell	-135	Closed	-$24.8K	–	951
2025 Q4	$24.8K	Buy	135 +83	+160%	+$14.6K	﹤0.01%	435
2025 Q3	$7.87K	Sell	52 -26	-33%	-$3.94K	﹤0.01%	509
2025 Q2	$10.9K	Buy	78 +27	+53%	+$3.78K	﹤0.01%	464
2025 Q1	$7.5K	Sell	51 -15	-23%	-$2.17K	﹤0.01%	498
2024 Q4	$8.62K	Buy	66 +16	+32%	+$2.24K	﹤0.01%	486
2024 Q3	$6.78K	Hold	50	–	–	﹤0.01%	437
2024 Q2	$7.8K	Sell	50 -230	-82%	-$34.6K	﹤0.01%	429
2024 Q1	$37.9K	Sell	280 -1	-0.4%	-$132	0.01%	315
2023 Q4	$37.8K	Buy	281 +67	+31%	+$8.71K	0.01%	295
2023 Q3	$29K	Buy	214 +169	+376%	+$23.1K	0.01%	303
2023 Q2	$6.44K	Buy	+45	New	+$6.62K	﹤0.01%	467

Other funds holding AZN

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $103B AUM 36.66% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

LBP AM Paris, France $11.2B AUM 34.48% 1-Year Est. Return

M&G plc London, United Kingdom $19.9B AUM 15.09% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Nemes Rush Group's AZN Position: Q3 2026 in Review

Nemes Rush Group held its AstraZeneca (AZN) position steady in Q3 2026 at 135 shares worth $21.8K. The position accounts for ﹤0.01% of the portfolio, ranked #461.

Nemes Rush Group first reported a position in AZN in Q2 2023 and has held it in 13 quarters since. The position peaked at $37.9K in Q1 2024. 844 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

Nemes Rush Group held 135 shares of AstraZeneca worth $21.8K as of Q3 2026.
Nemes Rush Group left its AstraZeneca share count unchanged in Q3 2026.
AstraZeneca made up ﹤0.01% of Nemes Rush Group's portfolio in Q3 2026, its #461 holding.
Nemes Rush Group first reported a position in AstraZeneca in Q2 2023 and has held it in 13 quarters since.
Nemes Rush Group's AstraZeneca position peaked at $37.9K in Q1 2024.
844 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.